Biotechnology News and Research

RSS

SG Austria, Nuvilex use live cell encapsulation technology and treat diabetes in animal model

Nuvilex, Inc. announced today their affiliate SG Austria and partners have successfully treated diabetes in an established, recognized animal model utilizing live encapsulated cells.

7 Dec 2011

FDA modifies requirements of Amgen's Nplate REMS Program

Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.

7 Dec 2011

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

Protalix BioTherapeutics, Inc., announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date of the New Drug Application (NDA) for taliglucerase alfa to May 1, 2012, a three-month extension from the previous PDUFA date of February 1, 2012.

6 Dec 2011

More mothers are breastfeeding their newborns, but for too short a duration

More mothers are breastfeeding their newborns, but for too short a duration to gain the maximum benefits of breastfeeding for both mothers and infants.

6 Dec 2011

Experts to explore neuroethics of memory at SUNY Downstate symposium

Recent advances in understanding how memory functions and how memories could potentially be erased medically have raised numerous ethical questions. Scientists, ethicists, and legal scholars will explore the neuroethics of memory at a symposium organized by SUNY Downstate Medical Center on Friday, December 9, at the SUNY Global Center, 116 East 55th Street, New York, New York.

6 Dec 2011

MorphoSys unveils next-generation antibody technology Ylanthia

MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.

6 Dec 2011

EMBL-EBI, BBSRC welcome UK funding announcement on behalf of life science community

The European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) and the Biotechnology and Biological Sciences Research Council (BBSRC) warmly welcome today's announcement from the UK Government of a £75 million commitment from the Department for Business, Innovation and Skills' Large Facilities Capital Fund (LFCF) for the ELIXIR research infrastructure.

6 Dec 2011

Biogen, Samsung partner to develop and market biosimilars

Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.

5 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

American Society of Hematology 2012 Scholar Awards announced

The American Society of Hematology (ASH) announces the recipients of its 2012 Scholar Awards. The ASH Scholar Awards provide monetary support for fellows and junior faculty pursuing research careers to assist them during the critical period in which they must complete their training and achieve status as an independent investigator.

3 Dec 2011

New technique allows production of medically useful amounts of endoderm cells from human PSCs

Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known as the 'valley of death'.

3 Dec 2011

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.

3 Dec 2011

Corning acquires Mediatech

Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.

2 Dec 2011

First results from whole-genome sequencing clinical trial on triple negative breast cancer

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin-(trastuzumab).

2 Dec 2011

Specific electromagnetic fields can block cancer cell growth

New evidence by University of Alabama at Birmingham researchers that specific electromagnetic fields can safely block the proliferation of cancer cells and tumor growth may help refine a new, targeted therapy without any collateral damage.

2 Dec 2011

Enrollment complete in Ceregene's CERE-120 Phase 2b trial for Parkinson's

Ceregene, Inc. reported today that it has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the neurturin (NRTN) gene for the treatment of Parkinson's disease.

1 Dec 2011

Corning completes acquisition of Mediatech

Corning Incorporated announced today that it has completed the acquisition of Mediatech, Inc., a Virginia-based corporation, including Mediatech's subsidiary, KD Medical, Inc., a Maryland-based corporation.

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Different brain structures control eye reflexes in the course of life

Structures in the midbrain that developed early in evolution can be responsible for functions in newborns which in adults are taken over by the cerebral cortex. New evidence for this theory has been found in the visual system of monkeys by a team of researchers from the RUB. The scientists studied a reflex that stabilizes the image of a moving scene on the retina to prevent blur, the so-termed optokinetic nystagmus.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011